BioPharma Resources

Drug Trial Radar · NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

A Multicenter, International, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel-group, 2-arm, Phase 3 Study to Compare the Efficacy and Safety of the Oral FXIa Inhibitor Asundexian (BAY 2433334) With Apixaban for the Prevention of Stroke or Systemic Embolism in Male and Female Participants Aged 18 Years and Older With Atrial Fibrillation at Risk for Stroke

Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 14,830 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

14,830

Actual

Start

Dec 5, 2022

Primary completion

Jan 31, 2024

Study completion Jan 31, 2024

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Dec 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat people with atrial fibrillation (AF) and prevent stroke or systemic embolism (blood clots travelling through the blood stream to plug another vessel). Atrial fibrillation is a condition of having irregular and often rapid heartbeat. It can lead to the formation of blood clots in the heart which can travel through the blood stream to plug another vessel, and like this lead to serious and life-threatening conditions, such as a stroke. A stroke occurs because the brain tissue beyond the blockage no longer receives nutrients and oxygen so that brain cells die. As strokes arising from atrial fibrillation can involve extensive areas of the brain, it is important to prevent them. Blood clots are formed in a process known as coagulation. Medications are already available to prevent the formation of blood clots. When taken by mouth (orally), they are known as oral anticoagulants (OACs) including apixaban. OACs decrease the risk of the above-mentioned serious and life-threatening conditions. The main side effect of OACs is an increase of the risk of bleeding. The study treatment asundexian is a new type of anticoagulant currently under development to provide further treatment options. Asundexian aims to further improve the standard of care with regard to the risk of bleeding. The main purpose of this study is to collect more data about how well asundexian works to prevent stroke and systemic embolism and how safe it is compared to apixaban in people with atrial fibrillation and at high risk for stroke. To see how well the study treatment asundexian works researchers compare: * how long asundexian works well and * how long apixaban works well after the start of the treatment. Working well means that the treatments can prevent the following from happening: * stroke and/or * systemic embolism. The study will keep collecting data until a certain number of strokes or embolisms happen in the study. To see how safe asundexian is, the researchers will compare how often major bleedings occur after taking the study treatments asundexian and apixaban, respectively. Major bleedings are bleedings that have a serious or even life-threatening impact on a person's health. The study participants will be randomly (by chance) assigned to 1 of 2 treatment groups, A and B. Dependent on the treatment group, the participants will either take the study treatment asundexian by mouth once a day or apixaban by mouth twice a day for approximately 9 - 33 months. Each participant will be in the study for approximately 9 - 34 months. There will be visits to the study site every 3 to 6 months and up to 7 phone calls. Those participants who do not want or are unable to have visits to the study site may join the study remotely in selected locations. The location name contains the abbreviation - DCT in such cases. During the study, the study team will: * take blood samples * do physical examinations * examine heart health using an electrocardiogram (ECG) * check vital signs such as blood pressure and heart rate * do pregnancy tests * ask the participants questions about their quality of life * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

Conditions

  • Prevention of Stroke or Systemic Embolism
  • Atrial Fibrillation

Interventions

  • Asundexian (BAY2433334)Drug

    Once a day

  • ApixabanDrug

    5 mg or 2.5 mg, twice a day, according to product label.

  • Asundexian matching placeboDrug

    Placebo to asundexian, once a day

  • Apixaban matching placeboDrug

    Placebo to apixaban, twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Composite of Stroke or Systemic EmbolismTime frame: Approximately 12 months
  2. Number of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major BleedingTime frame: Approximately 12 months
  3. Number of Participants With Composite of Stroke, Systemic Embolism, or ISTH Major BleedingTime frame: Approximately 12 months

Locations

1,069 sites in 38 countries. Site status is shown where the registry gives one.

  • SEC Clinical Research

    Dothan, Alabama

  • Eastern Shore Research Institute, LLC | Fairhope, AL

    Fairhope, Alabama

  • Mobile Heart Specialists, PC

    Mobile, Alabama

  • University of South Alabama Medical Center

    Mobile, Alabama

  • Arkansas Cardiology | Little Rock

    Little Rock, Arkansas

  • Valley Clinical Trials, Inc. | Covina, CA

    Covina, California

  • Science 37

    Culver City, California

  • University of California, Irvine

    Irvine, California

  • VA Long Beach Healthcare System

    Long Beach, California

  • VA Greater Los Angeles Healthcare System | West Los Angeles VA Medical Center - Cardiology Department

    Los Angeles, California

  • Radin Cardiovascular Medical Group

    Newport Beach, California

  • Amicis Research Center | Northridge, CA

    Northridge, California

  • Cottage Health | Santa Barbara Cottage Hospital - Cardiology Department

    Santa Barbara, California

  • NorthBay Clinical Research, LLC | Santa Rosa, CA

    Santa Rosa, California

  • The Lundquist Institute | Cardiology Department

    Torrance, California

  • Harbor - UCLA Medical Center

    Torrance, California

  • Blue Coast Research Center, LLC

    Vista, California

  • Interventional Cardiology Medical Group | West Hills, CA

    West Hills, California

  • University of Colorado Hospital - Cardiology

    Aurora, Colorado

  • South Denver Cardiology Associates, PC

    Littleton, Colorado

  • Cardiology Associates of Fairfield County, P.C. | Stamford, CT

    Norwalk, Connecticut

  • Integrity Clinical Research | Florida Premier Cardiology

    Boynton Beach, Florida

  • Integrity Clinical Research | Cardiology Associates of South Florida

    Boynton Beach, Florida

  • Cardiovascular & Vein Center of Florida | Bradenton, FL

    Bradenton, Florida

  • Nova Clinical Research | Brandenton, FL

    Bradenton, Florida

  • Clearwater Cardiovascular Associates | Clearwater, FL

    Clearwater, Florida

  • Cardiology Consultants, PA

    Daytona Beach, Florida

  • Cardiology Associates Research Company

    Daytona Beach, Florida

  • Integrity Clinical Research | Heller Heart Health

    Delray Beach, Florida

  • North Florida Foundation For Research And Education | Veterans Benefits Administration

    Gainesville, Florida

  • Indago Research and Health Center | Hialeah, FL

    Hialeah, Florida

  • Encore Research Group | Nature Coast Clinical Research - Inverness

    Inverness, Florida

  • University of Florida - Jacksonville

    Jacksonville, Florida

  • Heart Vein & Vascular | Longwood, FL

    Longwood, Florida

  • Life Spring Research | Miami, FL

    Miami, Florida

  • Southwest Florida Research | Naples, FL

    Naples, Florida

  • Advanced Research for Health Improvement, LLC | Naples, FL

    Naples, Florida

  • Cardiology Partners Clinical Research Institute | Palm Beach Gardens Office

    Palm Beach Gardens, Florida

  • Baptist Heart and Vascular/Cardiology Consultants

    Pensacola, Florida

  • Peace River Cardiovascular Center | Port Charlotte, FL

    Port Charlotte, Florida

Showing 40 of 1,069 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.